Thyroid Cancer

Drs Benjamin Levy and Lori J. Wirth comment on the current role of liquid biopsies in lung and thyroid cancer.

Recommendations for selecting appropriate patients for comprehensive genomic profiling and navigating through the testing process.

Drs Benjamin Levy and Lori J. Wirth describe how they currently utilize comprehensive genomic profiling to manage patients with non–small cell lung cancer or thyroid cancer.

New research sheds lights on the causes of thyroid cancer, overdiagnosis of PTC

Data from a recent study found that while the risk of developing cancer is 1.74 times greater for individuals born with major birth defects, that risk is highest in childhood but decreases slightly after age 20.

The drug has been approved to treat patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.

The most common symptoms of thyroid cancer are typically painless swelling in the front of the neck, below the Adam’s apple and difficulty swallowing.

For Thyroid Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.

Progress in treating rare cancers represents the most significant oncology advance of last year, ASCO says.

A new drug can break the circuit of cancer-causing effects that develop when certain genes fuse.

Cancer doesn’t discriminate. It doesn’t care what race, gender, ethnicity, sexuality or even age you are. It takes no prisoners. And it certainly did not take me. I continue to remain resilient despite what I’ve been through and despite what still may be on the horizon.

From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.

As a result of what I went through and my never-ending passion for helping others, I believe that my diagnosis happened for a reason – to lead me to a career in patient advocacy.

Survivor diagnosed with second cancer after surgeon spots a lump on her throat while watching TV.

The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.

From genetic mutations to treatment behind bars, here's a roundup of our 2018 Summer issue.

In this week’s episode of CURE Talks Cancer, we spoke with Voigt about how he noticed a lump in a woman’s neck while watching tv and utilized the power of social media to find her – which ultimately led to a thyroid cancer diagnosis.

Instead of undergoing surgery for potential cancer, many people with thyroid nodules can safely opt for surveillance.

High blood pressure is common in patients with thyroid cancer who are taking Lenvima. Here's what one expert says about managing it.

Cancer survivors worry about recurrence, but seldom think about their risk for new primaries.

The Food and Drug Administration (FDA) approved the two-drug combination Tafinlar (dabrafenib) and Mekinist (trametinib) to treat patients with metastatic or unresectable anaplastic thyroid cancer (ATC), whose tumors harbor the BRAF V600E mutation.

After being diagnosed with a rare cancer, professional runner Gabriele Grunewald became inspired to start a nonprofit that raised awareness for other rare cancers and empowered those who have them.

Tests like these are growing increasingly important, as TOO results lead to treatment changes about 65 percent of the time and a site treatment change about 35 percent of the time, according to Cancer Genetics.